Express News | Oric Pharmaceuticals Inc - Expect to Report Updated Phase 1B Data in First Half of 2025
Moomoo 24/7Apr 15 16:15 ET
Express News | Oric Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1B Trial of Oric-114 in Patients With Mutated Nsclc
Moomoo 24/7Apr 15 16:15 ET
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Omeros (OMER) and Urogen Pharma (URGN)
TipRanksApr 9 07:40 ET
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of
GlobeNewswireApr 5 16:30 ET
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of
GlobeNewswireApr 4 16:30 ET
Oric Pharmaceuticals Bolsters Incentive Plan to Attract Talent
TipRanksMar 29 16:33 ET
Oric Pharmaceuticals Is Maintained at Overweight by JP Morgan
Oric Pharmaceuticals Is Maintained at Overweight by JP Morgan
Dow JonesMar 27 10:51 ET
JP Morgan Maintains Overweight on ORIC Pharmaceuticals, Lowers Price Target to $18
JP Morgan analyst Anupam Rama maintains ORIC Pharmaceuticals with a Overweight and lowers the price target from $19 to $18.
Analyst UpgradesMar 27 10:40 ET
Micron To Rally Around 134%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Rosenblatt
BenzingaMar 21 09:15 ET
Oric Pharmaceuticals: Sustained Buy Rating Amid Strong Financials and Upcoming Catalysts
TipRanksMar 21 06:27 ET
Oric Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Oric Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow JonesMar 21 06:25 ET
Express News | HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Raises Price Target to $21
Moomoo 24/7Mar 21 06:15 ET
ORIC Pharmaceuticals Inc (ORIC) Reports Q4 and Full Year 2023 Financial Results
Yahoo FinanceMar 12 21:01 ET
These Analysts Revise Their Forecasts On ORIC Pharmaceuticals After Q4 Results
ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) reported a loss for the fourth quarter on Monday. ORIC Pharmaceuticals posted a quarterly loss of 49 cents per share, in-line with market estimates, according
BenzingaMar 12 12:55 ET
ORIC Pharmaceuticals Stock Target Raised to $17 on Strong Prospects
InvestingMar 12 10:04 ET
Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush
Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush
Dow JonesMar 12 08:32 ET
Analysts Conflicted on These Healthcare Names: Insmed (INSM), Oric Pharmaceuticals (ORIC) and CytomX Therapeutics (CTMX)
TipRanksMar 12 08:20 ET
Oric Pharmaceuticals Is Maintained at Outperform by Baird
Oric Pharmaceuticals Is Maintained at Outperform by Baird
Dow JonesMar 12 08:16 ET
Express News | Baird Maintains Outperform on ORIC Pharmaceuticals, Lowers Price Target to $25
Moomoo 24/7Mar 12 08:06 ET
ORIC Pharmaceuticals Files for Automatic Mixed Securities Shelf
Seeking AlphaMar 11 17:34 ET
No Data
No Data